News | October 22, 2013

EASE Study Successful for Phoenix Atherectomy System in Treating PAD

Study assessed safety and effectiveness of Phoenix System

October 22, 2013 — AtheroMed, a developer of catheter technologies for treating peripheral artery disease (PAD), announced results from its Endovascular Atherectomy Safety and Effectiveness (EASE) study during a late-breaking clinical trials session at the Vascular Interventional Advances (VIVA) 2013 conference in Las Vegas. Stephen Williams, M.D., director of the Vascular Medicine Center, Johns Hopkins University, presented the results of the study, which demonstrate the safety and effectiveness of the Phoenix atherectomy system in treating PAD.

EASE is a prospective, multicenter, single-arm study of 105 patients (123 lesions) in the United States and Germany that evaluated the Phoenix atherectomy system in the treatment of lesions in the lower extremity arteries. The Phoenix system is an atherectomy device that uses a front-cutting, low profile design to continuously cut, capture and clear atheroma from the patient without requiring specialized capital equipment. Co-principal investigators of the study are Thomas Davis, St. John Hospital, and James McKinsey, Columbia Presbyterian Hospital.

The results presented by Williams highlight that the Phoenix system achieved its pre-defined performance goals to demonstrate safety and effectiveness: 95.1 percent of the lesions treated achieved technical success, and, at 30 days, 94.3 percent of patients were free from major adverse events. Flow-limiting dissections (Grade C or D) were observed in 1.9 percent of lesions with bail-out stenting required in 0.95 percent of lesions. Intervention due to distal embolization was limited to 0.95 percent of lesions.

"The results from the EASE study are very encouraging and are consistent with pivotal trials for other atherectomy devices," said Williams. "With more than 70 percent of the patients in the study suffering from blockages at or below the knee, the Phoenix system is likely to be a promising treatment alternative for these challenging procedures."

"I was pleased to see the positive results of the EASE data released at VIVA," said Thomas Zeller, head of the department of angiology, Herzzentrum University in Bad Krozingen, Germany. "These results are in line with my own experience with the Phoenix catheter, and I look forward to it being made available to my patients in the near future."

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init